JP2015522561A - 高誘導型一酸化窒素合成酵素と関連する疾患を処置するためのガラクト−ラムノガラクツロネート組成物 - Google Patents
高誘導型一酸化窒素合成酵素と関連する疾患を処置するためのガラクト−ラムノガラクツロネート組成物 Download PDFInfo
- Publication number
- JP2015522561A JP2015522561A JP2015516198A JP2015516198A JP2015522561A JP 2015522561 A JP2015522561 A JP 2015522561A JP 2015516198 A JP2015516198 A JP 2015516198A JP 2015516198 A JP2015516198 A JP 2015516198A JP 2015522561 A JP2015522561 A JP 2015522561A
- Authority
- JP
- Japan
- Prior art keywords
- galacto
- rhamnogalacturonate
- kda
- diseases
- residues
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 37
- 201000010099 disease Diseases 0.000 title claims abstract description 35
- 239000000203 mixture Substances 0.000 title claims description 74
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 title description 49
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 title description 48
- 238000000034 method Methods 0.000 claims abstract description 41
- 238000011282 treatment Methods 0.000 claims abstract description 27
- 239000003814 drug Substances 0.000 claims abstract description 18
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 13
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 12
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 12
- 208000037976 chronic inflammation Diseases 0.000 claims abstract description 12
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims abstract description 12
- 230000004770 neurodegeneration Effects 0.000 claims abstract description 12
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 12
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 claims abstract description 11
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 claims abstract 10
- 150000001875 compounds Chemical class 0.000 claims description 116
- 102000007563 Galectins Human genes 0.000 claims description 38
- 108010046569 Galectins Proteins 0.000 claims description 38
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims description 27
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims description 23
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 22
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims description 19
- 210000002540 macrophage Anatomy 0.000 claims description 16
- 210000001616 monocyte Anatomy 0.000 claims description 16
- UNSKAUSCLTVFGO-KCDKBNATSA-N methyl (2s,3r,4s,5r)-2,3,4,5-tetrahydroxy-6-oxohexanoate Chemical compound COC(=O)[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O UNSKAUSCLTVFGO-KCDKBNATSA-N 0.000 claims description 15
- 238000009472 formulation Methods 0.000 claims description 13
- 210000004185 liver Anatomy 0.000 claims description 13
- 239000003112 inhibitor Substances 0.000 claims description 12
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 11
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 11
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 11
- 150000001720 carbohydrates Chemical class 0.000 claims description 11
- 229920000140 heteropolymer Polymers 0.000 claims description 11
- 210000001130 astrocyte Anatomy 0.000 claims description 10
- 210000004027 cell Anatomy 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 239000003833 bile salt Substances 0.000 claims description 9
- 235000014633 carbohydrates Nutrition 0.000 claims description 9
- 230000002829 reductive effect Effects 0.000 claims description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 230000028327 secretion Effects 0.000 claims description 8
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 claims description 7
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical group C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims description 7
- 239000003963 antioxidant agent Substances 0.000 claims description 7
- 235000006708 antioxidants Nutrition 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 239000002158 endotoxin Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 108010072051 Glatiramer Acetate Proteins 0.000 claims description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 6
- 230000003078 antioxidant effect Effects 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 210000001519 tissue Anatomy 0.000 claims description 6
- 230000035899 viability Effects 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 5
- FHGWEHGZBUBQKL-UHFFFAOYSA-N 1,2-benzothiazepine Chemical compound S1N=CC=CC2=CC=CC=C12 FHGWEHGZBUBQKL-UHFFFAOYSA-N 0.000 claims description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 4
- 102000011690 Adiponectin Human genes 0.000 claims description 4
- 108010076365 Adiponectin Proteins 0.000 claims description 4
- 101000695838 Homo sapiens Receptor-type tyrosine-protein phosphatase U Proteins 0.000 claims description 4
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical class C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 4
- 102100028516 Receptor-type tyrosine-protein phosphatase U Human genes 0.000 claims description 4
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 claims description 4
- 229960004308 acetylcysteine Drugs 0.000 claims description 4
- 230000000692 anti-sense effect Effects 0.000 claims description 4
- 239000003613 bile acid Substances 0.000 claims description 4
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 claims description 4
- 229960001091 chenodeoxycholic acid Drugs 0.000 claims description 4
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 claims description 4
- 229940099500 cystamine Drugs 0.000 claims description 4
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical group NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 claims description 4
- 229960003776 glatiramer acetate Drugs 0.000 claims description 4
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 4
- 239000000787 lecithin Substances 0.000 claims description 4
- 235000010445 lecithin Nutrition 0.000 claims description 4
- 229940067606 lecithin Drugs 0.000 claims description 4
- 239000003120 macrolide antibiotic agent Substances 0.000 claims description 4
- 229960003151 mercaptamine Drugs 0.000 claims description 4
- 150000003053 piperidines Chemical class 0.000 claims description 4
- 150000003856 quaternary ammonium compounds Chemical class 0.000 claims description 4
- 235000019156 vitamin B Nutrition 0.000 claims description 4
- 239000011720 vitamin B Substances 0.000 claims description 4
- 229940046001 vitamin b complex Drugs 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 3
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims description 3
- 102000015225 Connective Tissue Growth Factor Human genes 0.000 claims description 3
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 claims description 3
- 101001092910 Homo sapiens Serum amyloid P-component Proteins 0.000 claims description 3
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 3
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 3
- 102100036202 Serum amyloid P-component Human genes 0.000 claims description 3
- 229930003427 Vitamin E Natural products 0.000 claims description 3
- 229960005370 atorvastatin Drugs 0.000 claims description 3
- 235000021466 carotenoid Nutrition 0.000 claims description 3
- 150000001747 carotenoids Chemical class 0.000 claims description 3
- 238000003570 cell viability assay Methods 0.000 claims description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 3
- 229940121649 protein inhibitor Drugs 0.000 claims description 3
- 239000012268 protein inhibitor Substances 0.000 claims description 3
- 239000011669 selenium Substances 0.000 claims description 3
- 229910052711 selenium Inorganic materials 0.000 claims description 3
- 229960002855 simvastatin Drugs 0.000 claims description 3
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 3
- 150000003384 small molecules Chemical class 0.000 claims description 3
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 claims description 3
- 229960001661 ursodiol Drugs 0.000 claims description 3
- 229940046009 vitamin E Drugs 0.000 claims description 3
- 235000019165 vitamin E Nutrition 0.000 claims description 3
- 239000011709 vitamin E Substances 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 claims 18
- 238000003556 assay Methods 0.000 claims 5
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims 2
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 claims 2
- NIGNBCLEMMGDQP-UHFFFAOYSA-N 1-benzothiepine Chemical class S1C=CC=CC2=CC=CC=C12 NIGNBCLEMMGDQP-UHFFFAOYSA-N 0.000 claims 2
- 230000010705 Peroxisome Proliferator-activated Receptor Activity Effects 0.000 claims 2
- 150000002515 isoflavone derivatives Chemical class 0.000 claims 2
- 230000001737 promoting effect Effects 0.000 claims 2
- 239000002464 receptor antagonist Substances 0.000 claims 2
- 229940044551 receptor antagonist Drugs 0.000 claims 2
- 239000002469 receptor inverse agonist Substances 0.000 claims 2
- 102000003960 Ligases Human genes 0.000 claims 1
- 108090000364 Ligases Proteins 0.000 claims 1
- 102000004316 Oxidoreductases Human genes 0.000 claims 1
- 108090000854 Oxidoreductases Proteins 0.000 claims 1
- 229940122344 Peptidase inhibitor Drugs 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 238000009650 gentamicin protection assay Methods 0.000 claims 1
- 230000009149 molecular binding Effects 0.000 claims 1
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 20
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 20
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 17
- 229920001282 polysaccharide Polymers 0.000 description 17
- 239000005017 polysaccharide Substances 0.000 description 17
- 239000000243 solution Substances 0.000 description 16
- 229930182830 galactose Natural products 0.000 description 15
- 150000004676 glycans Chemical class 0.000 description 15
- 235000010987 pectin Nutrition 0.000 description 15
- 229920001277 pectin Polymers 0.000 description 15
- 239000001814 pectin Substances 0.000 description 15
- 238000001802 infusion Methods 0.000 description 13
- -1 polysaccharide compound Chemical class 0.000 description 13
- 230000037396 body weight Effects 0.000 description 12
- 235000000346 sugar Nutrition 0.000 description 12
- 102000000802 Galectin 3 Human genes 0.000 description 9
- 108010001517 Galectin 3 Proteins 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000001990 intravenous administration Methods 0.000 description 7
- 210000005228 liver tissue Anatomy 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 238000007920 subcutaneous administration Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 6
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000006198 methoxylation reaction Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 5
- 239000010949 copper Substances 0.000 description 5
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- 241000220225 Malus Species 0.000 description 4
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 4
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 4
- 235000010323 ascorbic acid Nutrition 0.000 description 4
- 239000011668 ascorbic acid Substances 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000009702 cancer cell proliferation Effects 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 150000002772 monosaccharides Chemical class 0.000 description 4
- 150000002978 peroxides Chemical class 0.000 description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- 208000004930 Fatty Liver Diseases 0.000 description 3
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 3
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 3
- 102000004856 Lectins Human genes 0.000 description 3
- 108090001090 Lectins Proteins 0.000 description 3
- 206010040070 Septic Shock Diseases 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000004761 fibrosis Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 229910001385 heavy metal Inorganic materials 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000002523 lectin Substances 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 241000219310 Beta vulgaris subsp. vulgaris Species 0.000 description 2
- 241000207199 Citrus Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102100034543 Fatty acid desaturase 3 Human genes 0.000 description 2
- 108010087894 Fatty acid desaturases Proteins 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 239000004378 Glycyrrhizin Substances 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- RWSXRVCMGQZWBV-PHDIDXHHSA-N L-Glutathione Natural products OC(=O)[C@H](N)CCC(=O)N[C@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-PHDIDXHHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- 229930064664 L-arginine Natural products 0.000 description 2
- 235000014852 L-arginine Nutrition 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 2
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 2
- 101710090055 Nitric oxide synthase, endothelial Proteins 0.000 description 2
- 229920002230 Pectic acid Polymers 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000004669 Protein-Lysine 6-Oxidase Human genes 0.000 description 2
- 108010003894 Protein-Lysine 6-Oxidase Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000021536 Sugar beet Nutrition 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000005349 anion exchange Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 229940093761 bile salts Drugs 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000020971 citrus fruits Nutrition 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 229940038717 copaxone Drugs 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 239000003395 histamine H3 receptor antagonist Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 230000002584 immunomodulator Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 229940125425 inverse agonist Drugs 0.000 description 2
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 2
- 235000008696 isoflavones Nutrition 0.000 description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 2
- 235000019136 lipoic acid Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000013425 morphometry Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000010318 polygalacturonic acid Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 2
- 235000017700 silymarin Nutrition 0.000 description 2
- 229960004245 silymarin Drugs 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 229960002663 thioctic acid Drugs 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 2
- 229910052723 transition metal Inorganic materials 0.000 description 2
- 229910001428 transition metal ion Inorganic materials 0.000 description 2
- 150000003624 transition metals Chemical class 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 239000002076 α-tocopherol Substances 0.000 description 2
- 235000004835 α-tocopherol Nutrition 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 102000000795 Galectin 1 Human genes 0.000 description 1
- 108010001498 Galectin 1 Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010051920 Glomerulonephropathy Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 101000998969 Homo sapiens Inositol-3-phosphate synthase 1 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 102100036881 Inositol-3-phosphate synthase 1 Human genes 0.000 description 1
- 235000011430 Malus pumila Nutrition 0.000 description 1
- 235000015103 Malus silvestris Nutrition 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 206010051606 Necrotising colitis Diseases 0.000 description 1
- 102100022397 Nitric oxide synthase, brain Human genes 0.000 description 1
- 101710111444 Nitric oxide synthase, brain Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 1
- 235000008422 Schisandra chinensis Nutrition 0.000 description 1
- 240000006079 Schisandra chinensis Species 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 235000015197 apple juice Nutrition 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 229910052798 chalcogen Inorganic materials 0.000 description 1
- 150000001787 chalcogens Chemical class 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 238000005734 heterodimerization reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 150000002771 monosaccharide derivatives Chemical class 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000000569 multi-angle light scattering Methods 0.000 description 1
- 208000004995 necrotizing enterocolitis Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007372 neural signaling Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000024121 nodulation Effects 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- LFULEKSKNZEWOE-UHFFFAOYSA-N propanil Chemical compound CCC(=O)NC1=CC=C(Cl)C(Cl)=C1 LFULEKSKNZEWOE-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004648 relaxation of smooth muscle Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000000580 secretagogue effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000003567 thiocyanates Chemical class 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/738—Cross-linked polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Description
本願は、2012年6月6日に出願された、米国仮出願第61/656,288号に基づく優先権の利益を主張し、その記載全体は引用により本願明細書に包含される。
本発明は、自己免疫疾患、慢性炎症性疾患、神経変性疾患、または心血管疾患を含む、高誘導型一酸化窒素合成酵素(iNOS)と関連する疾患を処置するための方法に関する。
一酸化窒素合成酵素(NOS)は、L−アルギニンからの一酸化窒素(NO)の形成を触媒する1つの酵素ファミリーである。NOは、重要な細胞シグナル伝達分子である。一酸化窒素は、正常な生理的細胞内および細胞外制御機能を有するが、一酸化窒素の過剰形成は、有害となり得ることが多い。
本発明は、高iNOS活性と関連する疾患を有するヒト対象を、許容される医薬担体中にガラクトース含有多糖類化合物を含む、非経腸または経腸投与用治療組成物を用いて処置する方法に関する。
本発明の詳細な態様を本明細書中に記載している。しかしながら、開示している態様は、種々の形態の態様をとり得る本発明を単に説明するためのものであことが理解されるべきである。さらに、本発明の種々の態様に関連する実施例の各々は、例示を目的とするものであり、限定を目的とするものではない。さらに、図面は必ずしも一定の縮尺である必要はなく、特定の構成要素の詳細を示すようにいくつかの特徴が誇張されていてもよい。さらに、図中に示す任意の測定、記載などは、例示を意図するためのものであって、限定を目的とするものではない。従って、本明細書に記載の特定の構造的および機能的な詳細は、限定のためのものと解するべきではなく、本発明を様々な形で用いることを当業者に教示するための典型的な基準に過ぎないと解されるべきである。
以下は、治療用多糖の製造を説明する実施例であって、本発明を限定することを意図するものではない。この場合、製造されたガラクト−ラムノガラクツロネートは、本発明においてGR−MD−02と標記されている。
本実施例において使用する実験モデルは、糖尿病を誘発し、高脂肪食を与えたマウスで、STAMマウスと称されているモデルである。生後すぐにストレプトゾトシンの単回注射によって糖尿病を誘発させ、4週間後にマウスに高脂肪食を与え始める。これは、マウスが確実に脂肪性肝炎を発症し、それに伴い肝細胞脂肪蓄積、肝細胞毒性の証拠、門脈および小葉の炎症性浸潤、類洞周囲線維症、結節形成を伴う進行性線維症、肝硬変、および究極的な肝細胞癌(動物のある割合)を発症することが証明されているモデルである。
Claims (45)
- 許容される医薬担体中にガラクト−ラムノガラクツロネートを含む非経腸または経腸投与用組成物を得て(ここで、該ガラクト−ラムノガラクツロネートは、α−1,2−結合ラムノースおよびα−1,4−結合GalA残基の交互オリゴマーである分岐へテロポリマーを結合する、1,4−結合ガラクツロン酸(GalA)およびメチルガラクツロネート(MeGalA)残基の主鎖を含み、該ラムノース残基は、1,4−β−D−ガラクトース残基のオリゴマーである主な分岐を有する。)、
有効量の該組成物を、それを必要とする対象に投与する工程(該投与により、疾患の影響を受ける組織におけるiNOSの発現が少なくとも10%減少することの少なくとも1つの結果がもたらされ、該対象が、自己免疫性疾患、慢性炎症性疾患、神経変性疾患、または心血管疾患を含む高iNOSと関連する疾患を有する。)
を含む、方法。 - 許容される医薬担体中にガラクト−ラムノガラクツロネートを含む非経腸または経腸投与用組成物を得て(ここで、該ガラクト−ラムノガラクツロネートは、α−1,2−結合ラムノースおよびα−1,4−結合GalA残基の交互オリゴマーである分岐へテロポリマーを結合する、1,4−結合ガラクツロン酸(GalA)およびメチルガラクツロネート(MeGalA)残基の主鎖を含むガラクト−ラムノガラクツロネートであり、該ラムノース残基は1,4−β−D−ガラクトース残基、1,5−α−L−アラビノース残基またはそれらの組み合わせのオリゴマーである主な分岐を有する。)、
有効量の該組成物を、それを必要とする対象に投与する工程(該投与により、疾患の影響を受ける組織におけるiNOSの発現が少なくとも10%減少することの少なくとも1つの結果がもたらされ、該対象が、自己免疫性疾患、慢性炎症性疾患、神経変性疾患、または心血管疾患を含む高iNOSと関連する疾患を有する。)
を含む、方法。 - 1,4−β−D−ガラクトースおよび1,5−α−L−アラビノース残基が、2:1ないし3:1の比で存在する、請求項2に記載の方法。
- 1,4−β−D−ガラクトース残基、1,5−α−L−アラビノース残基またはそれらの組み合わせが、炭水化物の総モルの少なくとも10モル%の量で存在する、請求項2ないし3のいずれか一項に記載の方法。
- ガラクト−ラムノガラクツロネートが、キシロース、グルコース、フコース残基またはそれらの組み合わせをさらに含む、請求項1ないし4のいずれか一項に記載の方法。
- ガラクト−ラムノガラクツロネートが、5kDa〜55kDaの範囲の平均分子量を有する、請求項1ないし5のいずれか一項に記載の方法。
- ガラクト−ラムノガラクツロネートが、2kDa〜80kDaの範囲の平均分子量を有する、請求項1ないし6のいずれか一項に記載の方法。
- ガラクト−ラムノガラクツロネートが、20kDa〜70kDaの範囲の平均分子量を有する、請求項1ないし7のいずれか一項に記載の方法。
- ガラクト−ラムノガラクツロネートが、2kDa〜65kDaの範囲の平均分子量を有する、請求項1ないし8のいずれか一項に記載の方法。
- ガラクト−ラムノガラクツロネートが、45kDa〜65kDaの範囲の平均分子量を有する、請求項1ないし9のいずれか一項に記載の方法。
- ガラクト−ラムノガラクツロネートが、2kDa〜20kDaの範囲の平均分子量を有する、請求項1ないし10のいずれか一項に記載の方法。
- ガラクト−ラムノガラクツロナン化合物を、エンドトキシンによりストレスを受けた単球またはマクロファージを処理するアッセイにおいて使用するとき、該アッセイにより、活性化単球またはマクロファージからのTNFαサイトカインが低下する、請求項1ないし11のいずれか一項に記載の方法。
- ガラクト−ラムノガラクツロナン化合物が、活性化単球または活性化マクロファージによるTNFαの分泌を少なくとも25%低下させることができる、請求項12に記載の方法。
- ガラクト−ラムノガラクツロナン化合物を、細胞生存アッセイにおいて、LX2不死化ヒト肝臓星状細胞の処理に用いたとき、該処理により、ガラクト−ラムノガラクツロナン化合物の投与後に活性化した肝臓星状細胞の生存率を実質的に低下させない、請求項1ないし13のいずれか一項に記載の方法。
- ガラクト−ラムノガラクツロネートを投与する工程において、該化合物を有効量の治療剤と共投与する、請求項1ないし14のいずれか一項に記載の方法。
- 該治療剤が、システアミンもしくはその薬学的に許容される塩、シスタミンもしくはその薬学的に許容される塩、抗酸化化合物、レシチン、ビタミンB複合体、胆汁塩製剤、カンナビノイド−1(CB1)受容体アンタゴニスト、カンナビノイド−1(CB1)受容体インバースアゴニスト、ペルオキシソーム増殖剤活性化受容体活性調節剤、ベンゾチアゼピンもしくはベンゾチエピン化合物、タンパク質チロシンホスファターゼPTPRUを阻害するRNAアンチセンス構築物、ヘテロ原子結合置換ピペリジンおよびその誘導体、アザシクロペンタン誘導体、アディポネクチンの分泌促進または誘導活性を有するアシルアミド化合物、第四級アンモニウム化合物、グラチラマーアセテート、ペントラキシンタンパク質、HMG−CoAレダクターゼ阻害剤、N−アセチルシステイン、イソフラボン化合物、マクロライド抗生物質、ガレクチン阻害剤、抗体、またはそれらの組み合わせ、の1つである、請求項15に記載の方法。
- 抗酸化化合物が、水溶性ビタミンE製剤、カロテノイド混合物、セレン、またはそれらの組み合わせを含む、請求項16に記載の方法。
- 胆汁塩製剤が、ウルソデオキシコール酸、天然に生じる胆汁酸もしくは胆汁酸塩のケノデオキシコール酸、合成胆汁酸もしくは胆汁酸塩のケノデオキシコール酸、またはそれらの組み合わせを含む、請求項16に記載の方法。
- ペントラキシンタンパク質が、組換えペントラキシン−2である、請求項16に記載の方法。
- HMG−CoAレダクターゼ阻害剤が、アトルバスタチン、シンバスタチンまたはそれらの組み合わせを含む、請求項16に記載の方法。
- ガレクチン阻害剤が、低分子有機ガレクチン阻害剤、モノクローナル抗体、RNA阻害剤、低分子結合ペプチド、タンパク質阻害剤、またはそれらの組み合わせを含む、請求項16に記載の方法。
- 抗体が、抗リシルオキシダーゼ抗体、または結合組織増殖因子に対する抗体である、請求項16に記載の方法。
- 自己免疫疾患、慢性炎症性疾患、神経変性疾患、または心血管疾患を含む高iNOSと関連する疾患の処置のための医薬組成物の製造におけるガラクト−ラムノガラクツロネート化合物(ここで、該ガラクト−ラムノガラクツロネートが、α−1,2−結合ラムノースおよびα−1,4−結合GalA残基の交互オリゴマーである分岐へテロポリマーを結合する、1,4−結合ガラクツロン酸(GalA)およびメチルガラクツロネート(MeGalA)残基の主鎖を含み、該ラムノース残基が、1,4−β−D−ガラクトース残基のオリゴマーである主な分岐を有する。)の使用。
- 自己免疫疾患、慢性炎症性疾患、神経変性疾患、または心血管疾患を含む高iNOSと関連する疾患の処置のための医薬組成物の製造におけるガラクト−ラムノガラクツロネート化合物(ここで、該ガラクト−ラムノガラクツロネートが、α−1,2−結合ラムノースおよびα−1,4−結合GalA残基の交互オリゴマーである分岐へテロポリマーを結合する、1,4−結合ガラクツロン酸(GalA)およびメチルガラクツロネート(MeGalA)残基の主鎖を含み、該ラムノース残基が、1,4−β−D−ガラクトース残基、1,5−α−L−アラビノース残基、またはそれらの組み合わせのオリゴマーである主な分岐を有する、ガラクトアラビノ−ラムノガラクツロネートである。)の使用。
- 1,4−β−D−ガラクトース残基および1,5−α−L−アラビノース残基が、2:1ないし3:1の比で存在する、請求項24に記載の使用。
- 1,4−β−D−ガラクトース残基、1,5−α−L−アラビノース残基またはそれらの組み合わせが、炭水化物の総モルの少なくとも10モル%の量で存在する、請求項24に記載の使用。
- ガラクト−ラムノガラクツロネートが、5kDa〜55kDaの範囲の平均分子量を有する、請求項23ないし26のいずれか一項に記載の使用。
- ガラクト−ラムノガラクツロネートが、2kDa〜80kDaの範囲の平均分子量を有する、請求項23ないし26のいずれか一項に記載の使用。
- ガラクト−ラムノガラクツロネートが、20kDa〜70kDaの範囲の平均分子量を有する、請求項23ないし26のいずれか一項に記載の使用。
- ガラクト−ラムノガラクツロネートが、2kDa〜65kDaの範囲の平均分子量を有する、請求項23ないし26のいずれか一項に記載の使用。
- ガラクト−ラムノガラクツロネートが、45kDa〜65kDaの範囲の平均分子量を有する、請求項23ないし26のいずれか一項に記載の使用。
- ガラクト−ラムノガラクツロネートが、2kDa〜20kDaの範囲の平均分子量を有する、請求項23ないし26のいずれか一項に記載の使用。
- 自己免疫疾患、慢性炎症性疾患、神経変性疾患、または心血管疾患を含む高iNOSと関連する疾患の処置のための、ガラクト−ラムノガラクツロネートおよび治療剤を含む混合物であって、該ガラクト−ラムノガラクツロネートが、α−1,2−結合ラムノースおよびα−1,4−結合GalA残基の交互オリゴマーである分岐へテロポリマーを結合する、1,4−結合ガラクツロン酸(GalA)およびメチルガラクツロネート(MeGalA)残基の主鎖を含み、該ラムノース残基が、1,4−β−D−ガラクトース残基のオリゴマーである主な分岐を有する、混合物。
- 自己免疫疾患、慢性炎症性疾患、神経変性疾患、または心血管疾患を含む高iNOSと関連する疾患の処置のための、ガラクト−ラムノガラクツロネートおよび治療剤を含む混合物であって、該ガラクト−ラムノガラクツロネートが、α−1,2−結合ラムノースおよびα−1,4−結合GalA残基の交互オリゴマーである分岐へテロポリマーを結合する、1,4−結合ガラクツロン酸(GalA)およびメチルガラクツロネート(MeGalA)残基の主鎖を含み、該ラムノース残基が、1,4−β−D−ガラクトース残基、1,5−α−L−アラビノース残基、またはそれらの組み合わせのオリゴマーである主な分岐を有する、ガラクトアラビノ−ラムノガラクツロネートである、混合物。
- 該治療剤が、システアミンもしくはその薬学的に許容される塩、シスタミンもしくはその薬学的に許容される塩、抗酸化化合物、レシチン、ビタミンB複合体、胆汁塩製剤、カンナビノイド−1(CB1)受容体アンタゴニスト、カンナビノイド−1(CB1)受容体インバースアゴニスト、ペルオキシソーム増殖剤活性化受容体活性調節剤、ベンゾチアゼピンもしくはベンゾチエピン化合物、タンパク質チロシンホスファターゼPTPRUを阻害するRNAアンチセンス構築物、ヘテロ原子結合置換ピペリジンおよびその誘導体、アザシクロペンタン誘導体、アディポネクチン分泌促進または誘導活性を有するアシルアミド化合物、第四級アンモニウム化合物、グラチラマーアセテート、ペントラキシンタンパク質、HMG−CoAレダクターゼ阻害剤、N−アセチルシステイン、イソフラボン化合物、マクロライド抗生物質、ガレクチン阻害剤、抗体、またはそれらの組み合わせ、の1つである、請求項33または34に記載の混合物。
- 1,4−β−D−ガラクトースおよび1,5−α−L−アラビノース残基が、2:1ないし3:1の比で存在する、請求項34に記載の混合物。
- 1,4−β−D−ガラクトース残基、1,5−α−L−アラビノース残基またはそれらの組み合わせが、炭水化物の総モルの少なくとも10モル%の量で存在する。請求項34または36に記載の混合物。
- ガラクト−ラムノガラクツロネートが、5kDa〜55kDaの範囲の平均分子量を有する、請求項34ないし37のいずれか一項に記載の混合物。
- ガラクト−ラムノガラクツロネートが、2kDa〜80kDaの範囲の平均分子量を有する、請求項34ないし37のいずれか一項に記載の混合物。
- ガラクト−ラムノガラクツロネートが、20kDa〜70kDaの範囲の平均分子量を有する、請求項34ないし37のいずれか一項に記載の混合物。
- ガラクト−ラムノガラクツロネートが、2kDa〜65kDaの範囲の平均分子量を有する、請求項34ないし37のいずれか一項に記載の混合物。
- ガラクト−ラムノガラクツロネートが、45kDa〜65kDaの範囲の平均分子量を有する、請求項34ないし37のいずれか一項に記載の混合物。
- ガラクト−ラムノガラクツロネートが、2kDa〜20kDaの範囲の平均分子量を有する、請求項34ないし37のいずれか一項に記載の混合物。
- ガラクト−ラムノガラクツロナン化合物を、エンドトキシンによりストレスを受けた単球またはマクロファージを処理するアッセイにおいて使用するとき、該アッセイにより、活性化単球またはマクロファージからのTNFαサイトカインが少なくとも25%低下する、請求項34ないし43のいずれか一項に記載の混合物。
- ガラクト−ラムノガラクツロナン化合物を、細胞生存アッセイにおいて、LX2不死化ヒト肝臓星状細胞の処理に用いたとき、該アッセイにより、該化合物の投与後に活性化した肝臓星状細胞の生存率を実質的に低下させない、請求項34ないし43のいずれか一項に記載の混合物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261656288P | 2012-06-06 | 2012-06-06 | |
US61/656,288 | 2012-06-06 | ||
PCT/US2013/044478 WO2013184892A1 (en) | 2012-06-06 | 2013-06-06 | Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2015522561A true JP2015522561A (ja) | 2015-08-06 |
JP2015522561A5 JP2015522561A5 (ja) | 2016-07-14 |
JP6517141B2 JP6517141B2 (ja) | 2019-05-22 |
Family
ID=49712624
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015516198A Active JP6517141B2 (ja) | 2012-06-06 | 2013-06-06 | 高誘導型一酸化窒素合成酵素と関連する疾患を処置するためのガラクト−ラムノガラクツロネート組成物 |
Country Status (13)
Country | Link |
---|---|
US (1) | US9763974B2 (ja) |
EP (1) | EP2858651B1 (ja) |
JP (1) | JP6517141B2 (ja) |
KR (1) | KR102071739B1 (ja) |
CN (1) | CN104619329B (ja) |
AU (1) | AU2013271585B2 (ja) |
BR (1) | BR112014030534A2 (ja) |
CA (1) | CA2875979C (ja) |
ES (1) | ES2848538T3 (ja) |
IL (1) | IL236067B (ja) |
MX (1) | MX2014014979A (ja) |
WO (1) | WO2013184892A1 (ja) |
ZA (1) | ZA201409195B (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008011216A2 (en) * | 2006-05-16 | 2008-01-24 | Pro-Pharmaceuticals, Inc. | Galactose-pronged polysaccharides in a formulation for antifibrotic therapies |
KR101968370B1 (ko) | 2011-12-28 | 2019-04-11 | 갈렉틴 테라퓨틱스, 인크. | 인간 질환의 치료를 위한 신규 탄수화물 약물의 조성물 |
US9763974B2 (en) | 2012-06-06 | 2017-09-19 | Galectin Therapeutics, Inc. | Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase |
CA2885970C (en) | 2012-09-17 | 2020-10-20 | Peter G. Traber | Method for enhancing specific immunotherapies in cancer treatment |
WO2014130648A1 (en) | 2013-02-20 | 2014-08-28 | Galectin Therapeutics, Inc. | Method for treatment of pulmonary fibrosis |
WO2016028714A1 (en) * | 2014-08-18 | 2016-02-25 | Pharmagenesis, Inc. | Polygalacturonan rhamnogalacturonan1 (pgrg1) composition |
CN112672765A (zh) | 2018-06-29 | 2021-04-16 | 格莱科斯生物医药公司 | 结合物 |
WO2021064729A1 (en) * | 2019-10-02 | 2021-04-08 | Patchor Ltd. | Injectable composition for the treatment of musculoskeletal disorders and methods of use thereof |
US20230038373A1 (en) | 2019-12-18 | 2023-02-09 | Glykos Biomedical Oy | Stabile conjugate |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10117800A (ja) * | 1996-08-30 | 1998-05-12 | Akita Pref Gov | 単糖、オリゴ糖または可溶化多糖の製造法 |
JP2002514663A (ja) * | 1998-05-13 | 2002-05-21 | キャリングタン、ラバラトーリズ、インク | アロエペクチン |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US583A (en) | 1838-01-27 | Hviprovement in horizontal windmills | ||
US7897A (en) | 1851-01-14 | Improvement in raising carriage-tops | ||
US2132577A (en) | 1934-08-28 | 1938-10-11 | Gen Foods Corp | Method of preparing pectin |
US2444266A (en) | 1944-03-31 | 1948-06-29 | Us Agriculture | Pectic materials and method of preparing same |
US2503258A (en) | 1948-01-23 | 1950-04-11 | Us Agriculture | Neutralization of pectinic acids with sodium bicarbonate |
US4016351A (en) | 1976-02-04 | 1977-04-05 | Eschinasi Emile H | Pectic substances with varying methoxyl content and process therefor |
US4268533A (en) | 1979-11-21 | 1981-05-19 | General Foods Corporation | Quick-set low methoxyl pectin composition |
JPS61502124A (ja) | 1984-05-09 | 1986-09-25 | ジ オ−ストラリアン ナシヨナル ユニヴア−シテイ− | 免疫応答の調節方法 |
US4686106A (en) | 1986-06-16 | 1987-08-11 | General Foods Corporation | Pectin food product |
US5071970A (en) | 1988-11-23 | 1991-12-10 | University Of Florida | Process for producing pectin with a high-to-medium methoxyl content from beet pulp |
DE4011285A1 (de) | 1990-04-06 | 1991-10-10 | Steigerwald Arzneimittelwerk | Arzneimittel zur behandlung von hyperlipidaemie und/oder atherosklerose |
US5605938A (en) | 1991-05-31 | 1997-02-25 | Gliatech, Inc. | Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate |
US7491708B1 (en) | 1993-03-01 | 2009-02-17 | David Platt | Modified pectin |
US5498702A (en) | 1993-12-16 | 1996-03-12 | California Natural Products | Treated pectinic acid process and product |
US5834442A (en) | 1994-07-07 | 1998-11-10 | Barbara Ann Karmanos Cancer Institute | Method for inhibiting cancer metastasis by oral administration of soluble modified citrus pectin |
US6297229B1 (en) | 1994-11-14 | 2001-10-02 | Mayo Foundation For Medical Education And Research | Use of ursodeoxycholic acid to treat nonalcoholic steatohepatitis |
US5760010A (en) | 1995-01-01 | 1998-06-02 | Klein; Ira | Method of treating liver disorders with a macrolide antibiotic |
US5681923A (en) | 1995-10-06 | 1997-10-28 | Platt; David | Tumor derived carbohydrate binding protein |
US6632797B2 (en) | 1996-06-24 | 2003-10-14 | Matti Siren | Method of treating angiogenesis |
US7022683B1 (en) * | 1998-05-13 | 2006-04-04 | Carrington Laboratories, Inc. | Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation |
US6180139B1 (en) | 1998-12-04 | 2001-01-30 | Viva America Marketing, Inc. | Composition and method for treating nonalcoholic steatohepatitis |
US6500807B1 (en) | 1999-02-02 | 2002-12-31 | Safescience, Inc. | Modified pectin and nucleic acid composition |
WO2000062076A1 (en) | 1999-04-13 | 2000-10-19 | Hsu Daniel K | Galectin expression is induced in cirrhotic liver and hepatocellular carcinoma |
WO2000062774A1 (en) | 1999-04-20 | 2000-10-26 | Board Of Trustees, Southern Illinois University | Methods of treating clinical diseases with isoflavones |
IT1316986B1 (it) | 2000-01-25 | 2003-05-26 | Sigma Tau Ind Farmaceuti | Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica. |
CN1142272C (zh) | 2000-02-02 | 2004-03-17 | 中国人民解放军军事医学科学院百环生物医学研究中心 | 携带人肝细胞生长因子基因的重组腺病毒的用途 |
WO2001056547A2 (en) | 2000-02-04 | 2001-08-09 | Seo Hong Yoo | Preparation of aqueous clear solution dosage forms with bile acids |
US6596762B2 (en) | 2001-05-17 | 2003-07-22 | The Regents Of The University Of Colorado | Antioxidant compositions and use for treatment of hepatic steatosis and steatohepatitis |
US6770622B2 (en) | 2001-06-08 | 2004-08-03 | Gary A. Jarvis | N-terminally truncated galectin-3 for use in treating cancer |
US6680306B2 (en) | 2001-06-21 | 2004-01-20 | Glycogenesys, Inc. | Method for enhancing the effectiveness of cancer therapies |
US20030004132A1 (en) | 2001-06-22 | 2003-01-02 | Yan Chang | Method and material for treating immune diseases |
KR20040019069A (ko) | 2001-07-20 | 2004-03-04 | 인터뮨, 인크. | 간섬유증의 치료 방법 |
US20040121981A1 (en) | 2001-11-21 | 2004-06-24 | Glycogenesys, Inc. | Method for controlling angiogenesis in animals |
US6890906B2 (en) | 2001-11-21 | 2005-05-10 | Glycogenesys, Inc. | Method for controlling angiogenesis in animals |
US7312208B2 (en) | 2002-08-28 | 2007-12-25 | Asahi Kasei Pharma Corporation | Quaternary ammonium compounds |
JP2004107295A (ja) | 2002-09-20 | 2004-04-08 | National Agriculture & Bio-Oriented Research Organization | ヒスタミン遊離抑制剤 |
EP1617849B1 (en) | 2003-04-07 | 2008-06-18 | Prospect Therapeutics, Inc. | Composition and uses of galectin antagonists |
US20040223971A1 (en) | 2003-04-07 | 2004-11-11 | Glycogenesys, Inc. | Composition and uses of galectin antagonists |
WO2004096998A2 (en) | 2003-04-29 | 2004-11-11 | Vanderbilt University | Nanoparticular tumor targeting and therapy |
US20050053664A1 (en) | 2003-09-08 | 2005-03-10 | Eliezer Zomer | Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer |
US7078064B2 (en) | 2003-12-03 | 2006-07-18 | George Zabrecky | Compositions and methods useful for treating and preventing chronic liver disease, chronic HCV infection and non-alcoholic steatohepatitis |
CN1930137B (zh) | 2004-02-27 | 2011-07-20 | 旭化成制药株式会社 | 苯并硫氮杂卓和苯并虑平化合物 |
EP2926818A1 (en) | 2004-03-26 | 2015-10-07 | La Jolla Pharmaceutical Company | Modified pectins, compositions and methods related thereto |
JP2008105945A (ja) | 2005-02-07 | 2008-05-08 | Ajinomoto Co Inc | アディポネクチンの分泌促進又は誘導作用を有するアシルアミド化合物 |
US7897583B2 (en) | 2005-05-24 | 2011-03-01 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to PTPRU |
MX2007014501A (es) | 2005-05-26 | 2008-02-07 | Metabasis Therapeutics Inc | Tiromimeticos novedosos que contienen acido fosfinico. |
KR20080021082A (ko) | 2005-06-20 | 2008-03-06 | 쉐링 코포레이션 | 히스타민 h3 길항제로서 유용한 피페리딘 유도체 |
WO2007016390A1 (en) | 2005-07-28 | 2007-02-08 | Children's Medical Center Corporation | Matrix metalloproteinase inhibitors for treating fatty liver disease |
US7906652B2 (en) | 2005-11-28 | 2011-03-15 | Merck Sharp & Dohme Corp. | Heterocycle-substituted 3-alkyl azetidine derivatives |
WO2008011216A2 (en) | 2006-05-16 | 2008-01-24 | Pro-Pharmaceuticals, Inc. | Galactose-pronged polysaccharides in a formulation for antifibrotic therapies |
JP5105297B2 (ja) | 2006-05-25 | 2012-12-26 | 味の素株式会社 | Ppar活性調節剤 |
EP2032570A4 (en) | 2006-06-13 | 2010-10-27 | Merck Frosst Canada Ltd | AZACYCLOPENTATE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME-A-DELTA-9-DESATURASE |
US7999107B2 (en) | 2007-01-31 | 2011-08-16 | Merck Sharp & Dohme Corp. | Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators |
JP5583022B2 (ja) | 2007-11-30 | 2014-09-03 | ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア | システアミン生成物を用いる非アルコール性脂肪性肝炎(nash)の治療方法 |
EP2260305A1 (en) | 2008-03-27 | 2010-12-15 | INSERM (Institut National de la Santé et de la Recherche Medicale) | Methods and kits for determining the occurrence of a liver disease in a subject |
KR101074158B1 (ko) | 2008-04-07 | 2011-10-17 | 재단법인 한국원자력의학원 | 간 보호 또는 간 질환의 예방 및 치료용 인삼다당체 조성물 |
US20110082119A1 (en) | 2008-06-13 | 2011-04-07 | Takashi Yano | Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis |
JP2010229099A (ja) | 2009-03-27 | 2010-10-14 | Mochida Pharmaceut Co Ltd | 脂質異常症の改善または治療薬 |
EP2732053B1 (en) | 2011-07-14 | 2017-10-25 | Progenity, Inc. | Systems, apparatus and methods for biochemical analysis |
US8658787B2 (en) * | 2011-09-16 | 2014-02-25 | Galectin Therapeutics Inc. | Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease |
KR101968370B1 (ko) * | 2011-12-28 | 2019-04-11 | 갈렉틴 테라퓨틱스, 인크. | 인간 질환의 치료를 위한 신규 탄수화물 약물의 조성물 |
US9763974B2 (en) | 2012-06-06 | 2017-09-19 | Galectin Therapeutics, Inc. | Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase |
CA2885970C (en) * | 2012-09-17 | 2020-10-20 | Peter G. Traber | Method for enhancing specific immunotherapies in cancer treatment |
-
2013
- 2013-06-06 US US14/405,280 patent/US9763974B2/en active Active
- 2013-06-06 CA CA2875979A patent/CA2875979C/en active Active
- 2013-06-06 KR KR1020147035737A patent/KR102071739B1/ko active IP Right Grant
- 2013-06-06 CN CN201380041782.7A patent/CN104619329B/zh active Active
- 2013-06-06 ES ES13800900T patent/ES2848538T3/es active Active
- 2013-06-06 MX MX2014014979A patent/MX2014014979A/es active IP Right Grant
- 2013-06-06 AU AU2013271585A patent/AU2013271585B2/en active Active
- 2013-06-06 BR BR112014030534A patent/BR112014030534A2/pt not_active Application Discontinuation
- 2013-06-06 EP EP13800900.6A patent/EP2858651B1/en active Active
- 2013-06-06 WO PCT/US2013/044478 patent/WO2013184892A1/en active Application Filing
- 2013-06-06 JP JP2015516198A patent/JP6517141B2/ja active Active
-
2014
- 2014-12-04 IL IL236067A patent/IL236067B/en active IP Right Grant
- 2014-12-12 ZA ZA2014/09195A patent/ZA201409195B/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10117800A (ja) * | 1996-08-30 | 1998-05-12 | Akita Pref Gov | 単糖、オリゴ糖または可溶化多糖の製造法 |
JP2002514663A (ja) * | 1998-05-13 | 2002-05-21 | キャリングタン、ラバラトーリズ、インク | アロエペクチン |
Non-Patent Citations (1)
Title |
---|
CHEN, CHIEN-HO ET AL.: "Suppression of endotoxin-induced proinflammatory responses by citrus pectin through blocking LPS sig", BIOCHEMICAL PHARMACOLOGY, vol. 72, no. 8, JPN6017002053, 2006, pages 1001 - 1009, ISSN: 0003485436 * |
Also Published As
Publication number | Publication date |
---|---|
US20150147338A1 (en) | 2015-05-28 |
CN104619329A (zh) | 2015-05-13 |
IL236067B (en) | 2020-11-30 |
CN104619329B (zh) | 2018-01-26 |
BR112014030534A2 (pt) | 2017-06-27 |
JP6517141B2 (ja) | 2019-05-22 |
AU2013271585B2 (en) | 2018-02-01 |
CA2875979C (en) | 2021-01-26 |
CA2875979A1 (en) | 2013-12-12 |
EP2858651A1 (en) | 2015-04-15 |
ES2848538T3 (es) | 2021-08-10 |
ZA201409195B (en) | 2015-09-30 |
AU2013271585A1 (en) | 2015-01-22 |
IL236067A0 (en) | 2015-01-29 |
US9763974B2 (en) | 2017-09-19 |
KR20150045409A (ko) | 2015-04-28 |
WO2013184892A1 (en) | 2013-12-12 |
KR102071739B1 (ko) | 2020-01-30 |
MX2014014979A (es) | 2015-06-17 |
EP2858651B1 (en) | 2020-11-11 |
EP2858651A4 (en) | 2016-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6517141B2 (ja) | 高誘導型一酸化窒素合成酵素と関連する疾患を処置するためのガラクト−ラムノガラクツロネート組成物 | |
JP6185473B2 (ja) | 非アルコール性脂肪性肝炎および非アルコール性脂肪肝疾患を処置するためのガラクト−ラムノガラクツロネート組成物 | |
US8828971B2 (en) | Galactose-pronged carbohydrate compounds for the treatment of diabetic nephropathy and associated disorders | |
EP2797942B1 (en) | Composition of novel carbohydrate drug for treatment of human diseases | |
Muñoz-Almagro et al. | Pectin from sunflower by-products obtained by ultrasound: Chemical characterization and in vivo evaluation of properties in inflammatory bowel disease | |
JP2008273911A (ja) | 顆粒球コロニー刺激因子産生促進物質 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20160217 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160525 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160525 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170131 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170426 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170614 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20170808 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171207 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20180131 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20180316 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20181122 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190124 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190417 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6517141 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |